4229=R-2 (12)

Patient: **GRIFFIN**, JACQUELINE

P O BOX 1272
PARRAMATTA NSW 2124

MRN: **5017741**

Loc: **DH**

Dob/Age: 10-JAN-1962 F/ 61 yrs Phone: **0408961344** Lab No: **885631821**

Research Institute

Australian Research Institute INC
ABN 14 539 575 487
A Medical Research Institute of Sydney Adventist Hospital

REPORT

185 Fox Valley Rd
Wahroonga NSW 2076
Telephone 02 9487 9601
Facsimile 02 9487 9626

Chief Scientist: A/Prof Ross Grant
B.Ed(Sc) MAppSc(ClinChem), PhD(NeuroPharm)

DOUGLASS HANLY MOIR PATHOLOGY
Quality is in our DNA

GRIFFIN, JACQUELINE

885631821

(W16659)

Report To:
DR YIFANG WU
NORTHSIDE HLTH NT

PO BOX 751
NIGHTCLIFF NT 0814

(PST/---/---/---/---)

Collected: 27/04/23 15:22
eported: 18/05/23 08:55
inted: 18/05/23 08:55

ecimen: BLOOD

NAD+ (whole blood)	44.3	umol/L WB

While a reference range has NOT yet been established typical values fall within the following parameters: NAD+ [15-35 uM]

The clinical relevance of this marker is currently unknown. However, it has been shown to inversely correlate with inflammatory and oxidative stress activity(1,2). Low NAD(H) levels have also been correlated with increased DNA damage(2) and reduced activity of the protective, NAD+ dependent deacetylase enzyme, Sirt1(2).
This test is performed using a research validated method.

References:

1) Guest J, Grant R, etal. J.Neuroinflamm 11:117-127 (2014)
2) Massudi H, Grant R, etal PLoS One 7:(7):e42357 (2012)